AllianceBernstein’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

AllianceBernstein’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-40,300	Closed	-$201K	–	3461
2021 Q1	$201K	Hold	40,300	–	–	﹤0.01%	3066
2020 Q4	$509K	Hold	40,300	–	–	﹤0.01%	2581
2020 Q3	$396K	Hold	40,300	–	–	﹤0.01%	2653
2020 Q2	$401K	Buy	40,300 +4,300	+12%	+$41.2K	﹤0.01%	2745
2020 Q1	$318K	Hold	36,000	–	–	﹤0.01%	2594
2019 Q4	$332K	Hold	36,000	–	–	﹤0.01%	2738
2019 Q3	$212K	Hold	36,000	–	–	﹤0.01%	2928
2019 Q2	$432K	Buy	36,000 +8,700	+32%	+$93.6K	﹤0.01%	2672
2019 Q1	$330K	Buy	27,300 +1,900	+7%	+$28K	﹤0.01%	2713
2018 Q4	$319K	Buy	25,400 +2,100	+9%	+$29K	﹤0.01%	2699
2018 Q3	$346K	Buy	23,300 +1,200	+5%	+$18.9K	﹤0.01%	2782
2018 Q2	$372K	Buy	22,100 +4,400	+25%	+$85.5K	﹤0.01%	2724
2018 Q1	$405K	Buy	17,700 +3,900	+28%	+$86.7K	﹤0.01%	2582
2017 Q4	$357K	Buy	13,800 +1,300	+10%	+$26.2K	﹤0.01%	2654
2017 Q3	$184K	Hold	12,500	–	–	﹤0.01%	2964
2017 Q2	$174K	Buy	+12,500	New	+$184K	﹤0.01%	3024

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AllianceBernstein's CNCE Position: Q2 2021 in Review

AllianceBernstein sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2021, closing a stake of 40,300 shares — an estimated $201K sold.

AllianceBernstein first reported a position in CNCE in Q2 2017 and held it in 16 quarters. The position peaked at $509K in Q4 2020. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2021.

AllianceBernstein reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
AllianceBernstein sold 40,300 Concert Pharmaceuticals, Inc. shares in Q2 2021, an estimated $201K.
AllianceBernstein first reported a position in Concert Pharmaceuticals, Inc. in Q2 2017 and held it in 16 quarters.
AllianceBernstein's Concert Pharmaceuticals, Inc. position peaked at $509K in Q4 2020.
79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.